Mycoplasma: A Key Component in Lyme and Other Diseases

The Organism Most Doctors Don’t Test For

If you have been dealing with chronic illness — whether it carries a diagnosis of Lyme disease, chronic fatigue syndrome, fibromyalgia, autoimmune disease, or unexplained cognitive decline — there is a significant probability that mycoplasma is involved. And there is an equally significant probability that no one has tested for it.

Mycoplasma are the smallest known self-replicating organisms. They are not quite bacteria, not quite viruses — they occupy a unique biological category that falls between conventional diagnostic boundaries. This in-between status is part of the reason they are so frequently missed. They do not grow on standard bacterial culture plates. They do not respond to the most commonly prescribed antibiotics. And they are not included in routine diagnostic panels for most of the diseases they contribute to.

At the Frequency Research Foundation, Dr. Jeff Sutherland has observed mycoplasma in over 80% of people tested — a finding consistent with other independent researchers in the field. Understanding mycoplasma is not a niche concern. It is central to understanding why so many chronic diseases persist despite treatment.

How Mycoplasma Work: The Cellular Mechanism

What makes mycoplasma uniquely dangerous is their method of survival. They are intracellular parasites — meaning they enter human cells and live inside them, using the cell’s own resources to survive and reproduce.

The Invasion Process

Mycoplasma enter individual cells and, depending on genetic predisposition, may target different tissues in different people. If the pathogen destroys cells in the brain, neurological disease may develop. If it invades and destroys cells in the lower bowel, conditions like Crohn’s colitis may follow. If it targets joint tissues, rheumatoid arthritis or other collagen-vascular diseases may result.

This tissue-specific targeting explains one of the most puzzling aspects of mycoplasma-related illness: why the same organism produces such different diseases in different people. The answer lies in individual genetic predisposition and which tissues the mycoplasma infiltrate.

The Dormancy Problem

One of mycoplasma’s most challenging characteristics is their ability to lie dormant inside cells for extended periods — potentially 10, 20, or even 30 years. During dormancy, they cause no symptoms and are virtually undetectable. They can be triggered into active infection by trauma, surgery, vaccination reactions, severe stress, immune suppression, or co-infection with other pathogens.

This dormancy-activation pattern explains many cases of sudden-onset chronic illness in previously healthy individuals. A triggering event activates dormant mycoplasma, which then begins destroying host cells and provoking immune responses that produce chronic symptoms.

How They Kill Cells

Because mycoplasma lack the organelles to process their own nutrients, they survive by uptaking pre-formed sterols (essential fats) from the host cell. They literally consume the cell from within. When the cell is depleted, it ruptures and its contents — including inflammatory debris and mycoplasma progeny — are dumped into the bloodstream. This triggers immune activation and inflammation, while the released mycoplasma invade new cells and repeat the cycle.

This mechanism explains the fluctuating, relapsing-remitting symptom pattern that is characteristic of mycoplasma-related illness. Periods of relative calm alternate with flare-ups as cycles of cellular invasion, destruction, and immune response repeat.

Mycoplasma and the Lyme Disease Complex

The Frequency Research Foundation’s most extensive clinical experience with mycoplasma involves its role in Lyme disease. Mycoplasma is not a secondary or minor component of Lyme — it is a key factor driving chronic symptoms.

Clinical Observations

Dr. Jeff Sutherland’s clinical experience has revealed several consistent patterns. Mycoplasma fermentans is present in virtually all Lyme infections observed at the Foundation. When mycoplasma fermentans is targeted with frequencies, it produces what appear to be Brucella infections — both organisms must be targeted together along with several other pathogens for effective treatment.

Lyme infections are found in over 80% of the people Dr. Sutherland tests, a finding consistent with other researchers working in this area. The mycoplasma component is typically the most persistent element of the Lyme complex, outlasting spirochetes and most co-infections.

Why Mycoplasma Make Lyme Chronic

Standard Lyme treatment targets Borrelia spirochetes. Even when these are successfully eliminated, mycoplasma continue to cycle through invasion, dormancy, and reactivation — producing the fatigue, cognitive symptoms, and immune dysfunction that characterize “chronic Lyme.”

Our companion article Mycoplasma – Why the Lyme Flu Goes On and On examines this persistence pattern in detail, including the complicating role of nanobacteria within mycoplasma and the Herxheimer reactions that occur during treatment. For our latest comprehensive Lyme treatment protocol, see Update: Lyme Frequencies Version 11.0.

The Disease Associations: Far Beyond Lyme

Research from multiple independent investigators has linked pathogenic mycoplasma to a remarkably wide range of chronic diseases. This is not speculative — it is documented by senior researchers at major institutions.

Key Research Citations

Dr. Shyh-Ching Lo, a senior researcher at the Armed Forces Institute of Pathology and one of America’s leading mycoplasma researchers, has documented Mycoplasma fermentans in patients with AIDS, cancer, chronic fatigue syndrome, Crohn’s colitis, type 1 diabetes, multiple sclerosis, Parkinson’s disease, Wegener’s disease, collagen-vascular diseases including rheumatoid arthritis, and Alzheimer’s disease. Dr. Lo holds a US patent on Mycoplasma fermentans isolated from patients.

Dr. Charles Engel of the US National Institutes of Health stated at an NIH meeting on February 7, 2000: “I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma.”

Dr. Maurice Hilleman, who served as chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by the vast majority of people in North America and potentially most people worldwide.

The Common Thread

The common thread across all these diseases is chronic immune activation and inflammation driven by an intracellular pathogen that the immune system recognizes but cannot effectively eliminate. Different tissues are affected in different people, producing different diagnostic labels — but the underlying mechanism is the same.

This connects directly to our foundational article Eliminating Inflammation Is a Top Priority for Disease Prevention. Mycoplasma are one of the most important drivers of the chronic inflammation that underpins heart disease, cancer, neurodegenerative disease, and autoimmune conditions.

Mycoplasma and Alzheimer’s Disease

The neurodegenerative implications of mycoplasma infection deserve particular attention within our Alzheimer’s research.

The Brain Infiltration Pathway

Mycoplasma can cross the blood-brain barrier and establish infections within brain tissue. Once there, they trigger the same destructive cycle that occurs in other tissues — cell invasion, sterol depletion, cell rupture, inflammatory response — but in the brain, the consequences are devastating.

Chronic microglial activation in response to mycoplasma creates persistent neuroinflammation. Neuronal energy depletion from mycoplasma parasitism impairs cognitive function. The inflammatory debris from ruptured cells contributes to the toxic environment that promotes amyloid accumulation.

Mycoplasma as Part of the Infectious Theory of Alzheimer’s

Mycoplasma is one of several chronic infections now linked to Alzheimer’s disease. The broader pattern — documented in our complete guide to Alzheimer’s disease and frequency therapy — involves multiple pathogen types contributing to the neuroinflammatory cascade that produces Alzheimer’s pathology.

Herpes simplex virus DNA has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus. Lyme spirochetes can directly invade brain tissue and trigger neuroinflammation. Mycoplasma add another layer of persistent, treatment-resistant infection that sustains the inflammatory environment.

For many Alzheimer’s patients, the disease may not have a single infectious cause but rather a combination of chronic infections — viral, bacterial, and mycoplasmal — each contributing to the neuroinflammatory burden. Addressing all of them is essential for a comprehensive treatment strategy.

Historical Context: The Origins of Pathogenic Mycoplasma

The question of how pathogenic mycoplasma became so widespread has been the subject of significant investigation. Researcher Donald W. Scott, MA, MSc, as president of the Common Cause Medical Research Foundation, compiled extensive documentation — drawing from US and Canadian government documents and peer-reviewed journals — suggesting that several mycoplasma strains were modified through biological warfare research programs dating from the 1940s onward.

According to Scott’s research, biological warfare programs in the United States, Canada, and Britain focused on weaponizing the Brucella bacterium, from which pathogenic mycoplasma were derived. Scott documented that these programs involved participation from the US Public Health Service, the CDC, and the NIH, and that the resulting organisms were tested on populations without informed consent.

These claims are supported by Scott’s collection of government documents, patents (including Dr. Lo’s US patent on Mycoplasma fermentans), and peer-reviewed publications from journals including the Journal of the American Medical Association, the New England Journal of Medicine, and the Canadian Medical Association Journal.

Whatever their precise origin, the clinical reality is that pathogenic mycoplasma are now ubiquitous and are contributing to chronic illness on a massive scale. Understanding how to detect and eliminate them is more immediately relevant than resolving the historical debate about their creation.

2026 Update: 20 Years of Advancement

Since this article was first published, understanding of mycoplasma’s role in chronic disease has advanced on multiple fronts.

Mainstream Recognition Is Growing

While mycoplasma remain underdiagnosed in conventional practice, the medical literature’s recognition of their role in chronic disease has expanded significantly. Mycoplasma are now acknowledged as potential contributors to a wider range of conditions than were recognized in 2005, and the mechanisms of intracellular parasitism and immune evasion are better understood.

The Microbiome Revolution

The explosion of microbiome research since 2005 has provided a broader framework for understanding how mycoplasma interact with other organisms in the body. Mycoplasma do not exist in isolation — they interact with the broader microbial ecosystem, and disruptions to the microbiome (from antibiotics, glyphosate, or other factors) can create conditions that favor mycoplasma proliferation.

Our article Glyphosate Alzheimer’s Disease: Could This Common Herbicide Increase Your Risk? covers how environmental toxins disrupt the microbial environment in ways that may favor pathogenic organisms like mycoplasma.

Frequency Protocol Refinement

The Frequency Research Foundation’s mycoplasma protocols have been refined extensively since 2005. Dr. Jeff Sutherland’s systematic approach now addresses a wider range of mycoplasma species and strains, accounts for the Brucella co-infections that emerge when mycoplasma fermentans is targeted, and manages the complex Herxheimer reactions that occur during treatment. The protocols are part of our comprehensive Lyme disease frequency protocol, Version 11.0.

Post-COVID Parallels

The COVID-19 pandemic created widespread awareness of post-infectious chronic illness. Long COVID symptoms — persistent fatigue, brain fog, immune dysfunction, chronic inflammation — closely mirror the symptom patterns of chronic mycoplasma infection. This parallel has made the medical community more receptive to the concept that organisms can persist after acute infection and drive chronic symptoms, opening doors for broader acceptance of mycoplasma’s role in chronic disease.

How Frequency Therapy Addresses Mycoplasma

Mycoplasma’s unique biology — no cell wall, intracellular residence, dormancy capability, multiple strains — demands an approach that conventional medicine is poorly equipped to provide. Frequency therapy offers distinct advantages for this particular organism.

Frequency Therapy’s Advantages Against Mycoplasma

Conventional antibiotics effective against mycoplasma (tetracyclines, macrolides, fluoroquinolones) face several limitations: they require months-long courses, they cannot reliably reach organisms inside host cells at therapeutic concentrations, and they cannot distinguish between mycoplasma strains.

Frequency therapy bypasses these limitations. Frequencies penetrate cell membranes and can reach intracellular organisms directly. Different frequencies can target different mycoplasma strains within the same treatment session. The approach can address the Brucella co-infections that emerge when Mycoplasma fermentans is disrupted. Nanobacteria within mycoplasma can be targeted as part of a sequential protocol.

The Clinical Approach

Dr. Jeff Sutherland’s approach to mycoplasma involves identifying which mycoplasma species and strains are present, targeting the mycoplasma and its associated Brucella component simultaneously, managing Herxheimer reactions through sequential treatment of internal co-infections, and supporting immune recovery as the infection burden is reduced.

This systematic, multi-organism approach reflects the clinical reality that mycoplasma infections are never simple, single-pathogen problems.

Chronic illness that won’t resolve? Mycoplasma may be the missing piece. Dr. Jeff Sutherland has over two decades of experience developing frequency protocols for mycoplasma and its co-infections. A paid consultation can identify whether mycoplasma is contributing to your symptoms and develop a targeted treatment plan. Book Your Consultation

Frequently Asked Questions

What diseases are linked to mycoplasma infection?

Research from Dr. Shyh-Ching Lo at the Armed Forces Institute of Pathology and other investigators has linked pathogenic mycoplasma to chronic fatigue syndrome, fibromyalgia, Lyme disease, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, rheumatoid arthritis, Crohn’s colitis, type 1 diabetes, cancer, and other chronic conditions. The common mechanism is intracellular parasitism that triggers chronic immune activation and inflammation, with different diseases resulting from mycoplasma targeting different tissues.

Why don’t most doctors test for mycoplasma?

Mycoplasma do not grow on standard bacterial culture plates and are not included in routine diagnostic panels. Most physicians are trained to test for common bacterial and viral infections using standard methods that do not detect mycoplasma. Specialized PCR testing is required, and most doctors are unfamiliar with ordering or interpreting these tests. Additionally, the role of mycoplasma in chronic disease — while well-documented in research literature — has not been widely integrated into clinical training.

Can mycoplasma lie dormant and then activate years later?

Yes. Mycoplasma can reside inside human cells in a dormant state for 10, 20, or even 30 years without causing symptoms. Triggering events — including physical trauma, surgery, severe stress, immune suppression, vaccination reactions, or co-infection with other pathogens — can activate dormant mycoplasma into a disease-causing state. This dormancy-activation pattern explains many cases of sudden-onset chronic illness in previously healthy individuals.

How is mycoplasma different from regular bacteria?

Mycoplasma are the smallest self-replicating organisms known. Unlike standard bacteria, they lack a cell wall — which makes them resistant to penicillin and most common antibiotics. They are intracellular parasites that live inside human cells, consuming the cell’s nutrients until the cell ruptures. Their small size, lack of cell wall, and intracellular lifestyle make them extremely difficult to detect through standard laboratory testing and resistant to conventional treatment approaches.

How does the Frequency Research Foundation treat mycoplasma?

Dr. Jeff Sutherland has developed a systematic, multi-stage frequency approach that targets mycoplasma organisms directly within host cells, addresses the Brucella co-infections that emerge when Mycoplasma fermentans is disrupted, manages nanobacteria released from dying mycoplasma, and targets multiple mycoplasma strains present in the Lyme disease complex. This sequential approach, refined over more than two decades, accounts for the biological complexity that makes mycoplasma one of the most challenging chronic infections to treat.

Take the Next Step

Mycoplasma is one of the most underdiagnosed and undertreated contributors to chronic illness worldwide. Whether your symptoms carry a label of Lyme disease, chronic fatigue, fibromyalgia, autoimmune disease, or cognitive decline, mycoplasma may be a key component driving the problem.

Dr. Jeff Sutherland has spent over 20 years developing frequency protocols specifically for mycoplasma and the complex co-infections that accompany them. A paid consultation is the most direct way to assess whether mycoplasma is a factor in your case.

Book Your Consultation with Dr. Jeff Sutherland

This article is part of our comprehensive Alzheimer’s resource library. Mycoplasma infections that infiltrate the brain contribute to the chronic neuroinflammation that drives Alzheimer’s progression. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, environmental toxins, nutritional strategies, and frequency-based treatment approaches.

© Frequency Research Foundation. This content is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease. Always consult with qualified healthcare professionals regarding medical conditions.

Cause, Spread, and Therapy of Lyme Disease

A Personal Encounter That Changed Everything

This article began with a personal experience. During a vacation, I was bitten by large mosquitoes and developed a massive, active Lyme infection. Using the frequency analysis methods developed at the Frequency Research Foundation, I went from having difficulty walking due to the crippling effects of the infection to being completely symptom-free in a matter of days.

But the real revelation came after the acute infection was resolved. Experiencing the full range of Lyme symptom patterns during the active infection, I realized something that reframed decades of my own health history: I had carried this infection before — since 1969. For almost 40 years, Lyme had caused chronic back pain, undiagnosed athletic injuries, and various sporadic symptoms that were never attributed to an infectious cause.

This personal experience underscored two critical truths about Lyme disease. First, it can remain chronic and lifelong, producing symptoms that are attributed to other causes for decades. Second, frequency therapy can resolve even severe, acute Lyme infections rapidly when the full constellation of pathogens is addressed.

The Athletic Performance Discovery

One of the most unexpected findings from my Lyme treatment was its effect on physical performance. As soon as I was symptom-free after clearing the acute infection, my two-mile running time decreased by more than 10% compared to my average for the month before the mosquito bites.

A 10% improvement in running performance is enormous. In competitive athletics, it is the difference between placing and not placing, between qualifying and failing to qualify. And this improvement came not from training harder or changing anything about my fitness regimen — it came solely from eliminating an infection I did not know was affecting my performance.

This has direct implications for every runner, cyclist, triathlete, and outdoor athlete. If you train outdoors regularly, your likelihood of Lyme infection is elevated. The infection may be silently compromising your performance even if you feel healthy and are in excellent training. You may be training at 90% of your capacity without knowing it — and attributing the gap to fitness, age, or genetics when the real cause is treatable.

How Widespread Is Lyme Disease?

The standard narrative about Lyme disease dramatically underestimates its prevalence. Based on over two decades of clinical testing at the Frequency Research Foundation, the picture that emerges is far more alarming than official statistics suggest.

What Clinical Testing Reveals

Over 90% of the people Dr. Jeff Sutherland has tested show detectable Lyme frequencies. These infections are typically chronic and lifelong. Most are undiagnosed because symptoms are expressed only when the immune system is depressed through injury, shock, disease episodes, cancer, or other incidents.

Based on these analyses, the Frequency Research Foundation estimates that more than 50% of the entire US population may be infected with the Lyme constellation of pathogens. Many disease syndromes, random symptoms, mysterious diseases, and so-called “psychosomatic” symptoms are actually manifestations of Lyme organisms operating below the threshold of clinical detection.

Official Numbers Keep Rising

Official statistics have steadily moved toward confirming what clinical testing suggested years ago. The CDC now estimates approximately 476,000 new Lyme cases per year in the United States — more than double earlier estimates. Lyme is reported in all 50 states. And these numbers capture only diagnosed cases; the actual number of infected individuals is certainly higher.

Transmission Routes Are Broader Than Acknowledged

The conventional view that Lyme is transmitted exclusively through tick bites does not match the clinical evidence. Research by Dr. Lida Mattman demonstrated recovery of live Borrelia spirochetes from mosquitoes, fleas, mites, semen, urine, blood, and spinal fluid. The Frequency Research Foundation’s clinical experience confirms that mosquito-borne transmission is a significant route — my own acute infection came from mosquito bites, not ticks.

The infected bodily fluids of carriers contain more than half a dozen different parasites, Borrelia, Babesia, Ehrlichia, and other pathogens. While all of them appear to be present in most infections, the majority may never be detected by standard laboratory tests.

The Lyme-Cancer Connection

Every person with cancer that Dr. Jeff Sutherland has tested has shown a Lyme infection. This is a consistent finding across cancer types and patient populations.

The mechanism is biologically plausible. Lyme organisms cause aberration of cells and growth of benign tumors. This means they alter DNA — and an organism that alters DNA is certainly a cofactor in cancer development, in addition to the other diseases associated with Lyme.

This does not mean that Lyme disease causes all cancer. It means that Lyme infection creates cellular conditions — chronic inflammation, immune dysfunction, DNA damage, and disrupted cellular growth regulation — that significantly increase cancer risk. For cancer patients, addressing an underlying Lyme infection may be an important component of comprehensive treatment that is currently being missed by conventional oncology.

Understanding the Full Lyme Complex

Lyme disease is not a single-organism infection. It is a complex of interacting pathogens that must all be addressed for successful treatment.

The Key Organisms

Borrelia burgdorferi spirochetes are the primary pathogen, capable of burrowing into tendons, muscle cells, ligaments, and organs including the brain. Ehrlichia infect white blood cells, compromising immune function from within. Babesia infect red blood cells, causing fatigue, sweats, and anemia-like symptoms — they are particularly difficult to eradicate. Multiple mycoplasma species create chronic fatigue, immune dysfunction, and neurological symptoms. Various parasites serve as reservoirs — they can be infected with other Lyme pathogens, and eliminating parasites can release the Lyme organisms they carry, causing reinfection.

This layered complexity is what makes Lyme disease so challenging. Addressing one pathogen without addressing the others leads to incomplete treatment and symptom recurrence.

The Neurotoxin Problem

Ehrlichia and Borrelia emit neurotoxic proteins that are extremely debilitating. These neurotoxins cause many of the most severe Lyme symptoms — cognitive dysfunction, nerve pain, muscle weakness, and the general feeling of being poisoned.

When eliminating these pathogens with frequencies, it is critical to have frequencies that deactivate the neurotoxins simultaneously. Otherwise, killing the organisms releases a flood of neurotoxins that makes the patient sicker — the classic Lyme Herxheimer effect. This is why many people who attempt Lyme treatment feel worse before they feel better, and why some abandon treatment prematurely.

At the Frequency Research Foundation, Dr. Jeff Sutherland’s protocols include neurotoxin-deactivating frequencies alongside pathogen-targeting frequencies, managing the Herxheimer reaction as an integral part of the treatment rather than an uncontrolled side effect.

The Dormancy Trigger

Lyme organisms can remain dormant for years or decades, kept in check by a functioning immune system. Symptoms emerge when the immune system is compromised by stress, injury, surgery, vaccination reactions, another illness, or aging. This explains why Lyme can appear to strike suddenly in someone who has no memory of a tick bite — they may have been carrying the infection silently for years.

Research has documented cases where symptoms appeared five years or more after the initial infection event. Mycoplasmal co-infections follow the same dormancy-activation pattern, as detailed in our article Mycoplasma: A Key Component in Lyme and Other Diseases.

The Connection to Alzheimer’s and Neurodegenerative Disease

Lyme disease’s ability to invade the brain directly connects it to neurodegenerative conditions including Alzheimer’s disease.

How Lyme Damages the Brain

Borrelia spirochetes can burrow directly into brain tissue, triggering chronic neuroinflammation. The neurotoxic proteins emitted by Borrelia and Ehrlichia cause direct neuronal damage. Mycoplasma co-infections, which cross the blood-brain barrier independently, add additional neuroinflammatory burden. The combined effect is persistent brain inflammation — the same process that drives Alzheimer’s disease progression.

Lyme in Neurodegenerative Disease Patients

Research by Dr. Lida Mattman recovered Borrelia from all tested cases of Alzheimer’s disease, 8 of 8 Parkinson’s cases, 41 multiple sclerosis cases, and 21 ALS cases. Our article Recent Research on Lyme Disease covers these findings in detail, including the remarkable recovery of several terminal ALS patients after appropriate Lyme treatment.

The Multi-Pathogen Theory of Alzheimer’s

Lyme is one component of a broader infectious picture in Alzheimer’s disease. Herpes simplex virus DNA has been found in 90% of Alzheimer’s plaques, as documented in our article Alzheimer’s and Herpes Simplex Virus. Mycoplasma, Borrelia, and viral infections may all contribute to the neuroinflammatory cascade.

For the complete picture of how infections, environmental toxins, nutrition, and frequency therapy all factor into Alzheimer’s disease, read our complete guide to Alzheimer’s disease and frequency therapy.

2026 Update: Two Decades of Clinical Experience

Since this article was first published, the Frequency Research Foundation’s understanding and treatment of Lyme disease has deepened through 20 additional years of clinical observation.

Protocol Evolution

The Lyme frequency protocols have been refined through continuous iteration. Our current protocol, Lyme Frequencies Version 11.0, addresses the full Lyme complex systematically — spirochetes, co-infections, neurotoxins, and parasitic reservoirs — in a sequenced approach that manages Herxheimer reactions throughout. Each version has incorporated new pathogen identifications and more refined frequency targeting.

The Post-COVID Parallel

The COVID-19 pandemic created millions of people with persistent post-infectious symptoms — long COVID — that closely mirror chronic Lyme: fatigue, brain fog, immune dysfunction, exercise intolerance, and chronic pain. This parallel has brought mainstream recognition to the concept that infections can persist and cause chronic illness, making the medical community more receptive to chronic Lyme as a legitimate condition.

Diagnostic Advances

While standard Lyme testing remains inadequate for detecting chronic and co-infections, advances in PCR testing, next-generation sequencing, and other molecular diagnostics have improved the ability to identify Borrelia and co-infections. Frequency-based assessment, as developed by the Frequency Research Foundation, continues to detect infections that laboratory testing misses.

The Chronic Inflammation Framework

The recognition that chronic inflammation drives most chronic disease — from heart disease to cancer to Alzheimer’s — provides a unifying framework for understanding how Lyme disease contributes to so many different conditions. Our article Eliminating Inflammation Is a Top Priority for Disease Prevention covers this foundational principle.

Therapy: The Frequency Approach to Lyme

The Frequency Research Foundation’s approach to Lyme disease therapy differs fundamentally from conventional antibiotic treatment.

Why Antibiotics Are Insufficient

Standard Lyme antibiotics target Borrelia spirochetes in their active, cell-walled form. They do not address cell wall deficient forms that evade antibiotic action, Ehrlichia inside white blood cells, Babesia inside red blood cells, mycoplasma co-infections that lack cell walls entirely, parasites that serve as pathogen reservoirs, or the neurotoxic proteins that cause Herxheimer reactions.

This is why many patients receive multiple rounds of antibiotics yet continue to have symptoms — the antibiotics address only one component of a multi-organism complex.

The Frequency Therapy Advantage

Frequency therapy can target each organism in the Lyme complex with specific frequencies. It can reach organisms inside cells. It can address cell wall deficient forms. Neurotoxin-deactivating frequencies can be applied simultaneously with pathogen-targeting frequencies. Parasitic reservoirs can be cleared to prevent reinfection. The entire complex can be addressed in a coordinated, sequenced protocol.

Dr. Jeff Sutherland’s personal experience — going from difficulty walking to symptom-free in days, followed by a 10% running performance improvement — demonstrates what is possible when the full Lyme complex is addressed comprehensively with frequencies.

Suspect Lyme disease may be affecting your health or performance? Over 90% of people tested at the Frequency Research Foundation show detectable Lyme frequencies. Dr. Jeff Sutherland offers personalized paid consultations to assess your infection status and develop a comprehensive frequency protocol. Book Your Consultation

Frequently Asked Questions

Can you get Lyme disease from mosquitoes?

Yes. While tick bites are the most commonly recognized transmission route, Dr. Lida Mattman recovered live Borrelia spirochetes from mosquitoes, fleas, and mites. Dr. Jeff Sutherland’s own acute Lyme infection was contracted from mosquito bites, not ticks. The conventional focus on tick-only transmission likely underestimates the true number of transmission events and infected individuals.

Can Lyme disease affect athletic performance?

Yes, significantly. After clearing a Lyme infection with frequency therapy, Dr. Jeff Sutherland’s two-mile running time improved by more than 10% — a massive performance gain from simply eliminating an infection. Athletes who train outdoors have elevated risk of Lyme infection, and the disease may silently compromise performance even in people who feel healthy and are in excellent training condition.

How many people actually have Lyme disease?

Official CDC estimates place new cases at approximately 476,000 per year in the United States. However, clinical testing at the Frequency Research Foundation detects Lyme frequencies in over 90% of people tested, suggesting that chronic, low-level Lyme infection may be far more prevalent than official statistics indicate. Most of these infections are undiagnosed because symptoms only appear when the immune system is compromised.

Does everyone with Lyme disease know they have it?

No. The majority of people with chronic Lyme infection are undiagnosed. The infection can remain dormant for years or decades, producing symptoms only when triggered by stress, injury, illness, or immune suppression. Many people with chronic back pain, unexplained fatigue, “mystery” symptoms, or neurodegenerative diagnoses may have an undetected underlying Lyme infection.

Is there a connection between Lyme disease and cancer?

Dr. Jeff Sutherland has found Lyme infection in every cancer patient tested at the Frequency Research Foundation. Lyme organisms cause cellular aberration, DNA alteration, and benign tumor growth — all of which create conditions favorable to cancer development. While Lyme disease may not directly cause cancer, it appears to be a significant cofactor that is currently overlooked by conventional oncology.

Take the Next Step

Lyme disease is far more common, more complex, and more consequential than conventional medicine acknowledges. Whether you are dealing with chronic unexplained symptoms, a known Lyme diagnosis that has not resolved with treatment, declining athletic performance, or a neurodegenerative condition, the Lyme complex may be a factor.

Dr. Jeff Sutherland has over 20 years of experience developing frequency protocols for the complete Lyme disease complex. A paid consultation can assess your situation and develop a targeted, comprehensive treatment plan.

Book Your Consultation with Dr. Jeff Sutherland

This article is part of our comprehensive Alzheimer’s resource library. Lyme disease and its co-infections contribute to the chronic neuroinflammation that drives Alzheimer’s and other neurodegenerative conditions. Read our complete guide to Alzheimer’s disease and frequency therapy for the full scope of research on infections, toxins, nutrition, and frequency-based treatment.